source · application/json
source_97ed2e8f13454cfb
sha256 db073ef98052bcf9082c269bf8346b8509ee4c1763117ed174c40924368efbaf
by researka:v2 · 2026-06-25 04:28:59.701511+04:00
{"publication_id": "825b123b-8868-470c-9e7e-9196adde37c5", "traces": [{"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "This paper synthesizes evidence on ABT-263 across 33 accepted source papers and 1290 high-confidence extracted claims.", "claim_id": "claim_1"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "The evidence profile contains 1 direct clinical source, 26 adjacent clinical sources, and 6 mechanistic or model-system sources, with 46 cross-study disagreements across the evidence base.", "claim_id": "claim_2"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "Positive study-level signals are summarized in the immune and inflammation, longevity, contextual adjacent evidence outcome classes, null signals in the contextual adjacent evidence, mechanism, immune and inflammation outcome classes, and negative signals in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.", "claim_id": "claim_3"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "The conclusion is that ABT-263 remains a bounded geroscience case: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "claim_id": "claim_4"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-senolytics-v06-DAILY-2026-06-25T00-24-59Z`.", "claim_id": "claim_5"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.", "claim_id": "claim_6"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.", "claim_id": "claim_7"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, immune and inflammation, longevity, mechanism, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.", "claim_id": "claim_8"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.", "claim_id": "claim_9"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.", "claim_id": "claim_10"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |", "claim_id": "claim_11"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "| Contextual Adjacent Evidence | n=14; claims=822 | no extracted directional signal in 11/14 sources | 10 indirect; 1 protocol; 3 review | limited corpus depth in this outcome class |", "claim_id": "claim_12"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.", "claim_id": "claim_13"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "14 included sources were assigned to this outcome class. Directional coding: null=11, positive=1, unclear=2. Directness coding: indirect=10, protocol=1, review=3.", "claim_id": "claim_14"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: review=2.", "claim_id": "claim_15"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "Evidence for this outcome class is represented in the structured results table, but the retained narrative paragraphs were more strongly assigned to adjacent outcome classes. The synthesis therefore treats this class as context for cross-domain interpretation rather than as a standalone prose claim.", "claim_id": "claim_16"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "4 included sources were assigned to this outcome class. Directional coding: null=4. Directness coding: mechanistic=4.", "claim_id": "claim_17"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "3 included sources were assigned to this outcome class. Directional coding: null=3. Directness coding: indirect=3.", "claim_id": "claim_18"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "3 included sources were assigned to this outcome class. Directional coding: mixed=1, null=2. Directness coding: direct=1, indirect=2.", "claim_id": "claim_19"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.", "claim_id": "claim_20"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.", "claim_id": "claim_21"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "The curated corpus is heavily skewed toward preclinical and indirect interventional hard-endpoint evidence, and the headline conclusions cannot be re-anchored to long-term, hard-outcome human RCTs. Several trials frequently invoked in the senolytic literature, including extension studies of dasatinib+quercetin in diabetic kidney disease, the SToMP-AD cerebrospinal-fluid penetration study, and the SToMP-AD phase 1 feasibility work, are represented only as protocols or as reports in which the field-relevant clinical endpoints are not powered to confirm or refute efficacy. Consequently, any synthesis-level claim of clinical benefit is built on a thin spine of direct human evidence and a thick base of mechanistic or surrogate work, and the gap between mechanistic plausibility and clinic-ready demonstration cannot be closed from this corpus alone.", "claim_id": "claim_22"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "Several outcome classes rest on a single source, and that single-source status is itself a within-corpus generalization risk that should be foregrounded. The directness asymmetry is also informative: Farr 2024 is the only source coded direct, while the surrounding directness=indirect and directness=mechanistic sources share no common endpoint definition, so a corroborating indirect signal cannot substitute for a missing direct one.", "claim_id": "claim_23"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "The populations enrolled in the direct and indirect human evidence are narrow, and the external-validity envelope is correspondingly tight. Shimizu 2025 randomized middle-aged humans to an Agrimonia pilosa extract. Outside these specific disease phenotypes, ages, and sex strata, the corpus offers no direct human signal: healthy community-dwelling older men, younger adults, and pediatric or non-European populations are absent. A substantial fraction of the supporting evidence is animal-only, including Falahatgaroshibi 2026 (male young Wistar rats, 10 and 30 mg/kg). Translational relevance to humans remains uncertain.", "claim_id": "claim_24"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "Finally, the mechanism-to-clinic gap is itself a corpus-level limitation that no individual RoB column can encode. The result is a corpus in which a coherent mechanistic story is told, but the clinically relevant dose, schedule, target population, and hard outcome remain undefined, and any cross-domain inference from mechanistic or surrogate sources onto a clinical recommendation must be treated as hypothesis-generating rather than evidence-supported.", "claim_id": "claim_25"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "For ABT-263, the final interpretation is deliberately tiered: the retained clinical and mechanistic evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.", "claim_id": "claim_26"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "This synthesis maps 33 included sources on Senolytics across 8 outcome classes and 46 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.", "claim_id": "claim_27"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "Across 33 curated reference papers, the evidence base for senolytics shows a context-dependent profile. Positive signals appear in: immune inflammation, longevity. Null findings dominate: contextual other, mechanism. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The senolytics anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.", "claim_id": "claim_28"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "Additional corpus sources included animal/preclinical evidence; the strongest unresolved contrast is the null vs positive between Mahoney 2025 and Schweiger 2025 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.", "claim_id": "claim_29"}, {"candidate_sources": [{"doi": "10.1016/j.ebiom.2023.104481", "study": "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability", "url": "https://doi.org/10.1016/j.ebiom.2023.104481"}, {"doi": "10.3390/ph19030431", "study": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke", "url": "https://doi.org/10.3390/ph19030431"}, {"doi": "10.1016/j.hrthm.2026.01.007", "study": "Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits", "url": "https://doi.org/10.1016/j.hrthm.2026.01.007"}, {"doi": "10.1111/acel.70500", "study": "Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12", "url": "https://doi.org/10.1111/acel.70500"}, {"doi": "10.1111/acel.13767", "study": "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age", "url": "https://doi.org/10.1111/acel.13767"}], "claim": "This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.", "claim_id": "claim_30"}]}
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "825b123b-8868-470c-9e7e-9196adde37c5",
"researka_submission_id": "ea11f591-877d-4c3b-a36d-280dd5de2f5b",
"sidecar_name": "citation_traces.json",
"sidecar_url": "https://api.researka.org/publications/825b123b-8868-470c-9e7e-9196adde37c5/sidecars/citation_traces.json"
}